Ken Griffin Intellia Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 59,200 shares of NTLA stock, worth $895,104. This represents 0.0% of its overall portfolio holdings.

Number of Shares

59,200

Previous 126,800 53.31%

Holding current value

$895,104

Previous $2.84 Million 57.14%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.72 - $27.36 $4.47 Million - $6.2 Million	226,759 Added 29.73%	989,439 $20.3 Million
Q2 2024 Aug 14, 2024	SELL	$20.02 - $27.22 $2.56 Million - $3.49 Million	-128,104 Reduced 14.38%	762,680 $17.1 Million
Q1 2024 May 15, 2024	SELL	$23.82 - $32.8 $8.78 Million - $12.1 Million	-368,508 Reduced 29.26%	890,784 $24.5 Million
Q4 2023 Feb 14, 2024	SELL	$23.16 - $32.34 $16.5 Million - $23 Million	-710,891 Reduced 36.08%	1,259,292 $38.4 Million
Q3 2023 Nov 14, 2023	BUY	$31.62 - $45.78 $11.6 Million - $16.7 Million	365,555 Added 22.78%	1,970,183 $62.3 Million
Q2 2023 Aug 14, 2023	BUY	$34.58 - $46.03 $15.1 Million - $20.1 Million	436,114 Added 37.32%	1,604,628 $65.4 Million
Q1 2023 May 15, 2023	SELL	$33.3 - $44.82 $1 Million - $1.35 Million	-30,171 Reduced 2.52%	1,168,514 $43.6 Million
Q4 2022 Feb 14, 2023	BUY	$33.21 - $62.69 $21.3 Million - $40.2 Million	641,551 Added 115.15%	1,198,685 $41.8 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $8.8 Million - $11.7 Million	163,196 Added 41.43%	557,134 $31.2 Million
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $3.56 Million - $7.05 Million	-92,495 Reduced 19.01%	393,938 $20.4 Million
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $16.3 Million - $33.3 Million	279,591 Added 135.17%	486,433 $35.3 Million
Q4 2021 Feb 14, 2022	BUY	$100.76 - $138.36 $6.78 Million - $9.32 Million	67,336 Added 48.27%	206,842 $24.5 Million
Q3 2021 Nov 15, 2021	SELL	$132.37 - $176.78 $22.8 Million - $30.5 Million	-172,591 Reduced 55.3%	139,506 $18.7 Million
Q2 2021 Aug 16, 2021	SELL	$60.88 - $161.91 $24.1 Million - $64.1 Million	-395,906 Reduced 55.92%	312,097 $50.5 Million
Q1 2021 May 17, 2021	SELL	$46.59 - $83.68 $19.6 Million - $35.3 Million	-421,396 Reduced 37.31%	708,003 $56.8 Million
Q4 2020 Feb 16, 2021	BUY	$18.83 - $63.53 $5.53 Million - $18.7 Million	293,613 Added 35.13%	1,129,399 $61.4 Million
Q3 2020 Nov 16, 2020	BUY	$17.47 - $24.93 $1.6 Million - $2.28 Million	91,359 Added 12.27%	835,786 $16.6 Million
Q2 2020 Aug 14, 2020	SELL	$11.14 - $22.87 $1.7 Million - $3.49 Million	-152,610 Reduced 17.01%	744,427 $15.6 Million
Q1 2020 May 15, 2020	BUY	$9.44 - $15.58 $2.39 Million - $3.95 Million	253,661 Added 39.43%	897,037 $11 Million
Q4 2019 Feb 14, 2020	BUY	$10.43 - $17.67 $5.6 Million - $9.49 Million	536,787 Added 503.6%	643,376 $9.44 Million
Q3 2019 Nov 14, 2019	SELL	$13.07 - $18.51 $682,959 - $967,221	-52,254 Reduced 32.9%	106,589 $1.42 Million
Q2 2019 Aug 14, 2019	BUY	$13.88 - $18.41 $981,857 - $1.3 Million	70,739 Added 80.29%	158,843 $2.6 Million
Q1 2019 May 15, 2019	BUY	$12.79 - $17.62 $795,013 - $1.1 Million	62,159 Added 239.58%	88,104 $0
Q4 2018 Feb 14, 2019	BUY	$11.39 - $27.13 $9,032 - $21,514	793 Added 3.15%	25,945 $354,000
Q3 2018 Nov 13, 2018	SELL	$25.78 - $32.6 $1.04 Million - $1.31 Million	-40,264 Reduced 61.55%	25,152 $0
Q1 2018 May 11, 2018	BUY	$19.43 - $34.95 $871,940 - $1.57 Million	44,876 Added 218.48%	65,416 $1.38 Million
Q4 2017 Feb 09, 2018	BUY	$17.39 - $31.12 $113,556 - $203,213	6,530 Added 46.61%	20,540 $395,000
Q3 2017 Nov 09, 2017	BUY	$15.16 - $25.75 $212,391 - $360,757	14,010	14,010 $348,000

Others Institutions Holding NTLA

# of Institutions

313

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.15B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account